Phase IV Study on QoL in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide
Inclusion Criteria:
1. Be at least 18 years of age
2. Have a confirmed diagnosis of MM
3. Starting lenalidomide treatment for MM (due to relapsed or refractory disease) after
one prior treatment.
4. Have personally signed and dated a legally effective written informed consent form
prior to admission to the study.
5. Must be willing and able to understand and comply with the study requirements.
Exclusion Criteria:
1. Individuals who have taken any experimental drugs or participated in a clinical trial
within 30 days prior to screening.
2. Individuals with significant psychiatric illness or a clinically significant
acute/chronic uncontrolled medical condition that might affect their experience of
myeloma symptoms or their ability to describe them.